These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23773101)

  • 1. Improving bladder cancer patient care: a pharmacoeconomic perspective.
    Gore JL; Gilbert SM
    Expert Rev Anticancer Ther; 2013 Jun; 13(6):661-8. PubMed ID: 23773101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the variation in treatment intensity among patients with early stage bladder cancer.
    Hollingsworth JM; Zhang Y; Krein SL; Ye Z; Hollenbeck BK
    Cancer; 2010 Aug; 116(15):3587-94. PubMed ID: 20564128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The costs of non-muscle invasive bladder cancer.
    James AC; Gore JL
    Urol Clin North Am; 2013 May; 40(2):261-9. PubMed ID: 23540783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The burden of bladder cancer care: direct and indirect costs.
    Mossanen M; Gore JL
    Curr Opin Urol; 2014 Sep; 24(5):487-91. PubMed ID: 24887047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional differences in early stage bladder cancer care and outcomes.
    Skolarus TA; Ye Z; Zhang S; Hollenbeck BK
    Urology; 2010 Aug; 76(2):391-6. PubMed ID: 20394976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical advances in bladder cancer: at what cost?
    Johnson DC; Greene PS; Nielsen ME
    Urol Clin North Am; 2015 May; 42(2):235-52, ix. PubMed ID: 25882565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer.
    Kulkarni GS; Alibhai SM; Finelli A; Fleshner NE; Jewett MA; Lopushinsky SR; Bayoumi AM
    Cancer; 2009 Dec; 115(23):5450-9. PubMed ID: 19685529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bladder and upper tract urothelial cancer.
    Konety BR; Joyce GF; Wise M
    J Urol; 2007 May; 177(5):1636-45. PubMed ID: 17437776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost of bladder tumour treatment and follow-up.
    Hedelin H; Holmäng S; Wiman L
    Scand J Urol Nephrol; 2002; 36(5):344-7. PubMed ID: 12487738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population.
    Schrag D; Mitra N; Xu F; Rabbani F; Bach PB; Herr H; Begg CB
    Urology; 2005 Jun; 65(6):1118-25. PubMed ID: 15922428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding bladder cancer death: tumor biology versus physician practice.
    Morris DS; Weizer AZ; Ye Z; Dunn RL; Montie JE; Hollenbeck BK
    Cancer; 2009 Mar; 115(5):1011-20. PubMed ID: 19152434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of bladder cancer care in the USA.
    Chamie K; Litwin MS
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):619-21. PubMed ID: 22098276
    [No Abstract]   [Full Text] [Related]  

  • 13. Can we still afford bladder cancer?
    Stenzl A; Hennenlotter J; Schilling D
    Curr Opin Urol; 2008 Sep; 18(5):488-92. PubMed ID: 18670272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Provider treatment intensity and outcomes for patients with early-stage bladder cancer.
    Hollenbeck BK; Ye Z; Dunn RL; Montie JE; Birkmeyer JD
    J Natl Cancer Inst; 2009 Apr; 101(8):571-80. PubMed ID: 19351919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The future of bladder cancer care in the USA.
    Kaplan AL; Litwin MS; Chamie K
    Nat Rev Urol; 2014 Jan; 11(1):59-62. PubMed ID: 23979659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis.
    Lotan Y; Svatek RS; Sagalowsky AI
    Cancer; 2006 Sep; 107(5):982-90. PubMed ID: 16862567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal management of high-risk T1G3 bladder cancer: a decision analysis.
    Kulkarni GS; Finelli A; Fleshner NE; Jewett MA; Lopushinsky SR; Alibhai SM
    PLoS Med; 2007 Sep; 4(9):e284. PubMed ID: 17896857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Candidate quality of care indicators for localized bladder cancer.
    Cooperberg MR; Porter MP; Konety BR
    Urol Oncol; 2009; 27(4):435-42. PubMed ID: 19573775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The excessive cost of early stage bladder cancer care: are providers really to blame?
    Hemani ML; Bennett CL
    Cancer; 2010 Aug; 116(15):3530-2. PubMed ID: 20564131
    [No Abstract]   [Full Text] [Related]  

  • 20. Quality of care: partial cystectomy for bladder cancer--a case of inappropriate use?
    Hollenbeck BK; Taub DA; Dunn RL; Wei JT
    J Urol; 2005 Sep; 174(3):1050-4; discussion 1054. PubMed ID: 16094056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.